MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Running, not enrolling · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Key facts

Study ID

NCT04649359

Run by

Pfizer

People needed

187

Starts

2021-02-02

Expected to finish

2026-12-31

Last updated by the study team

2026-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)
• Measurable disease, as defined by at least 1 of the following:
• Serum M-protein >0.5 g/dL by SPEP
• Urinary M-protein excretion >200 mg/24 hours by UPEP
• Serum immunoglobulin FLC≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
• Refractory to at least one IMiD
• Refractory to at least one PI
• Refractory to at least one anti-CD38 antibody
• Relapsed/refractory to last anti-myeloma regimen
• Cohort A: has not received prior BCMA-directed therapy
• Cohort B: has received prior BCMA-directed therapy (ADC or CAR T cells)
• ECOG performance status ≤2
• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1
• Not pregnant and willing to use contraception

You may not qualify if…

• Smoldering multiple myeloma
• Active Plasma cell leukemia
• Amyloidosis
• POEMS syndrome
• Stem cell transplant within 12 weeks prior to enrollment
• Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection
• Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
• Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)

Where it is running

• Beverly Hills Cancer Center — Beverly Hills, California, United States
• Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California, United States
• UCLA Hematology/Oncology Clinic — Los Angeles, California, United States
• UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California, United States
• Baptist Hospital of Miami — Miami, Florida, United States
• Miami Cancer Institute — Miami, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
• Blood and Marrow Transplant Group of Georgia — Atlanta, Georgia, United States
• Northwestern Medical Group — Chicago, Illinois, United States
• Northwestern Memorial Hospital — Chicago, Illinois, United States
• Loyola University Chicago performing research at Loyola University Medical Center — Maywood, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Norton Women's and Children's Hospital — Louisville, Kentucky, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Regional Cancer Care Associates, LLC — Hackensack, New Jersey, United States
• Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy — Long Island City, New York, United States
• Weill Cornell Medical College - New York Presbyterian Hospital — New York, New York, United States
• Weill Cornell Medical College - New York Presbyterian Hospital — New York, New York, United States
• St Francis Physician Services Inc — Greenville, South Carolina, United States
• Baylor Scott & White Research Institute — Dallas, Texas, United States
• St Vincent's Hospital (Melbourne) — Fitzroy, Victoria, Australia
• The Alfred — Melbourne, Victoria, Australia
• Epworth Healthcare — Richmond, Victoria, Australia
• CIUSSS-EMTL, Installation Hopital Maisonneuve-Rosemont — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.